Tag Archives: transcatheter aortic valve replacement

La prudencia es buena consejera para decidir una transfusión en el TAVI

Transfusion in TAVR: Caution Is Best

Transfusion in TAVR: Caution Is Best

Periprocedural red blood cell transfusion in transcatheter aortic valve replacement (TAVR) correlates with increased mortality and acute kidney injury. It also resulted an independent predictor of 30-day mortality, irrespective of bleeding and vascular complications.  The global trend that limits transfusion, in all procedures in general, has finally reached TAVR.  The multicenter registry TRITAVI (Transfusion Requirements

TAVI SURAVI

ProGlide vs. Prostar XL to Close Post-TAVR Access

Minimalist transcatheter aortic valve replacement (TAVR) is a strategy that is here to stay. We have previously published papers comparing local vs. general anesthesia, use of transthoracic vs. transesophageal echocardiography, and early discharge in TAVR. In all these papers, the “minimalist approach” included percutaneous closure of vascular access. However, few papers compare closure devices in

Enfermedad pulmonar y TAVI, solo se beneficia un grupo reducido de pacientes

Sapien Valve Keeps Delivering in Jobs for Which It Was Not Designed

We recently published the success of balloon-expandable Sapien valve when used as mitral valve replacement. We now hear about its success as pulmonary valve replacement. Previous experiences with this prosthesis for aortic valve replacement have encouraged many operators to attempt fixing other valves. At first, there were exceptional cases considered compassionate treatments. However, experience has

lotus

Boston Scientific Discontinues Lotus Valve and Makes a New Bet

Mechanically-expanding valve Lotus Edge was discontinued worldwide, as recently informed by its manufacturer, Boston Scientific. This is a voluntary recall of all Lotus valve inventory, and the immediate suspension of the program. The United States Food and Drug Administration (FDA) approved Lotus Edge in 2019 for patients with severe aortic stenosis and high surgical risk.

autoexpandible

Balloon-Expandable Valve Outdoes Itself

The objective of this paper recently published in J Am Coll Cardiol Intv was to compare the outcomes of transcatheter aortic valve replacement (TAVR) with the new Sapien 3 Ultra vs. Sapien 3. Successful implantation was extremely high with both balloon-expandable devices, which also had a very low adverse event rates. However, Sapien Ultra was significantly better

AHA 2020 | Anticoagulación post TAVI en pacientes con fibrilación auricular

AHA 2020 | Post-TAVR Anticoagulation in Patients with Atrial Fibrillation

Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation discharged after successful transcatheter aortic valve replacement (TAVR) compared with classic vitamin K inhibitors. Optimal anticoagulation in patients with atrial fibrillation (AF) undergoing TAVR is unclear. We are actually just starting to know what the ideal antiplatelet therapy is for patients undergoing

AHA 2020 | Aumenta el alta precoz en el TAVI con un costo esperado

AHA 2020 | Rise in Early Discharge After TAVR Has the Expected Cost

As hospitalization time after a transcatheter aortic valve replacement (TAVR) is reduced, we are observing a concomitant increase in re-hospitalizations due to conduction disorders. Early discharge is a great step, but it should be noted that conduction disorders can happen beyond 48 hours. A few years ago, pacemaker implantation rates after discharge were about 7%;

Sedación consciente vs anestesia general en el TAVI

Conscious Versus General Anesthesia in TAVR

Patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) can safely undergo the procedure under conscious sedation. Conscious sedation has been adopted in clinical practice as a natural way of simplifying and conducting the procedure in the least invasive way possible. Currently, up to 50% of patients undergo TAVR under conscious sedation, but

TCT 2020 | Eficacia del dispositivo de protección cerebral TriGUARD 3 durante el TAVI

TCT 2020 | Efficacy of Cerebral Protection Device TriGUARD 3 During TAVR

Cerebral protection device TriGUARD 3, designed to cover all supra-aortic vessels during transcatheter aortic valve replacement (TAVR), is safe to use, according to the outcomes of the REFLECT II study. The technical feasibility of the device, which requires transfemoral access, does not seem to have an impact over clinical events. The primary safety endpoint was a VARC-2-defined

TCT 2020 | La Acurate Neo no alcanza la no inferioridad vs la CoreValve Evolut

TCT 2020 | Acurate Neo Does Not Meet Non-Inferiority vs. CoreValve Evolut

The self-expanding Acurate Neo (Boston Scientific) did not meet non-inferiority vs. the self-expanding CoreValve Evolut (Medtronic) in the SCOPE 2 study published in Circulation simultaneously and presented at the virtual TCT 2020. These are bad news for the Acurate Neo, that had already failed to show non-inferiority vs. the Sapien 3 in the SCOPE 1

Top